Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tegliadine fumarate
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Tegliadine fumarate is a novel pharmaceutical agent currently under clinical investigation for the prevention of postoperative nausea and vomiting (PONV) and for postoperative pain management. It is being evaluated in adult women undergoing gynecologic laparoscopic surgery, where it is compared against standard treatments like sufentanil to assess its efficacy in controlling pain and nausea, as well as its impact on recovery quality and safety. The drug is administered via injection and is being studied in parallel-group interventional trials, notably at Taizhou First People's Hospital.
- Other names
- tegliadine fumaratetegliadine
Beyond the preview
Go deeper on tegliadine fumarate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tegliadine fumarate.